The NCCN published its first guidelines for pediatric bone sarcoma, centering on Ewing sarcoma and other undifferentiated round cell sarcomas in youth for pediatric patients.
|Videos|June 7, 2015
Drug Shows 10-Month Survival Improvement in Sarcoma
Author(s)William D. Tap, MD
In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma.
Advertisement
In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma. The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Advertisement
Related to this article
The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
2
Operationalizing the First Dose and Building the Oncology and Eye Care Partnership
3
Reading a Changed Eye Examination and Impact on Therapy
4
Personalizing Treatment Selection in Platinum-Resistant Ovarian Cancer
5